2023
Overall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery
Udelsman B, Canavan M, Zhan P, Ely S, Park H, Boffa D, Mase V. Overall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery. Journal Of Thoracic And Cardiovascular Surgery 2023, 167: 822-833.e7. PMID: 37500052, DOI: 10.1016/j.jtcvs.2023.07.021.Peer-Reviewed Original ResearchNon-small cell lung cancerStereotactic body radiotherapyStage I non-small cell lung cancerLow-comorbidity patientsCell lung cancerOverall survivalSurgical managementLung cancerSurgical resectionBody radiotherapyClinical stage I non-small cell lung cancerEarly-stage non-small cell lung cancerPropensity score-matched cohortPropensity score-matched patientsPropensity score-matched analysisEarly-stage lung cancerLong-term OSNational Cancer DatabaseProportion of patientsCancer DatabasePatientsSBRT patientsSurgeryCancerMortality
2022
A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation
Park HS, Detterbeck FC, Madoff DC, Bade BC, Kumbasar U, Mase VJ, Li AX, Blasberg JD, Woodard GA, Brandt WS, Decker RH. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813762, PMCID: PMC9264060, DOI: 10.21037/jtd-21-1826.Peer-Reviewed Original ResearchLong-term outcomesNon-randomized comparisonIndividual patientsSystematic reviewStage I lung cancerI lung cancerCharacteristics of patientsStage I NSCLCPulmonary function testsMinority of patientsShort-term outcomesStereotactic body radiotherapyThermal ablationLate toxicityPulmonary functionRandomized trialsFunction testsAdjusted comparisonsBody radiotherapyLung cancerResidual confoundingEffect modifiersShort-term benefitsPatientsPubMed systematic review
2018
Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis
Kann BH, Miccio JA, Stahl JM, Ross R, Verma V, Dosoretz AP, Park HS, Shafman TD, Gross CP, Yu JB, Decker RH. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis. Radiotherapy And Oncology 2018, 132: 188-196. PMID: 30391106, DOI: 10.1016/j.radonc.2018.10.017.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaStereotactic body radiotherapyAdjuvant systemic therapyEarly-stage non-small cell lung carcinomaSystemic therapyMulti-institutional analysisCell lung carcinomaOverall survivalST patientsBody radiotherapyLung carcinomaDefinitive stereotactic body radiotherapyEarly-stage NSCLC patientsClinical risk factorsRetrospective cohort studyKaplan-Meier methodHigher T stageTreatment of patientsMulti-institutional databasePropensity-score matchingPlatinum doubletsST cohortST regimenCohort studyNSCLC patients
2016
Spine Stereotactic Body Radiotherapy Outcomes in Patients with Concurrent Brain Metastases
Colaco RJ, Park HS, Laurans MS, Chiang VS, Yu JB, Husain ZA. Spine Stereotactic Body Radiotherapy Outcomes in Patients with Concurrent Brain Metastases. Cureus 2016, 8: e679. PMID: 27563505, PMCID: PMC4985044, DOI: 10.7759/cureus.679.Peer-Reviewed Original ResearchSpine stereotactic body radiotherapyConcurrent brain metastasisStereotactic body radiotherapyOverall survivalSpine metastasesLocal controlBrain metastasesMultivariable analysisOne-year local controlOne-year overall survivalCox proportional hazards regressionMedian patient ageProportional hazards regressionLog-rank testMann-Whitney testCBM patientsSurvival prognosticatorPain controlComplete stagingPatient ageSpinal metastasesClinical outcomesHazards regressionRadioresistant histologiesBody radiotherapy
2015
Racial disparities in the use of SBRT for treating early-stage lung cancer
Corso CD, Park HS, Kim AW, Yu JB, Husain Z, Decker RH. Racial disparities in the use of SBRT for treating early-stage lung cancer. Lung Cancer 2015, 89: 133-138. PMID: 26051446, DOI: 10.1016/j.lungcan.2015.05.002.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyUse of SBRTEarly-stage lung cancerBlack patientsExternal beam radiationWhite patientsAggressive therapyLung cancerRacial disparitiesNon-operative cohortNational Cancer DatabaseStage I NSCLCPrimary treatment modalitySurgical resection rateMultivariable logistic regressionPopulation-based studyPotential racial disparitiesInoperable candidatesSBRT useSBRT utilizationInoperable patientsResection rateSurgical resectionMultivariable analysisSurgical interventionCentral versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell Lung Cancer
Park HS, Harder EM, Mancini BR, Decker RH. Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell Lung Cancer. Journal Of Thoracic Oncology 2015, 10: 832-837. PMID: 25634007, DOI: 10.1097/jto.0000000000000484.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyBiological equivalent doseCentral tumor locationCell lung cancerOverall survivalTumor locationCentral tumorsLocal controlLung cancerBody radiotherapyPrimary non-small cell lung cancerNon-small cell lung cancerMultivariable logistic regression modelingMultivariable Cox regression modelingInoperable early stageProximal bronchial treeInferior overall survivalCox regression modelingKaplan-Meier analysisWorse overall survivalPeripheral tumor locationRegression modelingLogistic regression modelingAcute gradeCT1-2N0M0
2014
Does Central vs. Peripheral Tumor Location Impact Outcomes Following Stereotactic Body Radiotherapy for Non-Small Cell Lung Cancer?
Park H, Harder E, Mancini B, Decker R. Does Central vs. Peripheral Tumor Location Impact Outcomes Following Stereotactic Body Radiotherapy for Non-Small Cell Lung Cancer? International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s28-s29. DOI: 10.1016/j.ijrobp.2014.05.132.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerStereotactic body radiotherapyBody radiotherapyLung cancerImpact outcomesRadiotherapyCancerIncrease in the use of lung stereotactic body radiotherapy without a preceding biopsy in the United States
Rutter CE, Corso CD, Park HS, Mancini BR, Yeboa DN, Lester-Coll NH, Kim AW, Decker RH. Increase in the use of lung stereotactic body radiotherapy without a preceding biopsy in the United States. Lung Cancer 2014, 85: 390-394. PMID: 25001510, DOI: 10.1016/j.lungcan.2014.06.013.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStereotactic body radiotherapyBody radiotherapyStage I non-small cell lung cancerEarly-stage non-small cell lung cancerStage non-small cell lung cancerMultivariate analysisUse of SBRTLung stereotactic body radiotherapyLogistic regressionNational Cancer DatabasePercentage of patientsYear of diagnosisSmaller tumor sizeCell lung cancerMultivariate logistic regressionMedical inoperabilityMedical comorbiditiesInoperable patientsTumor sizeLung cancerCancer DatabaseEfficacious treatmentSBRT deliveryBiopsy